Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bausch + Lomb Corporation ( (BLCO) ) has provided an update.
Bausch + Lomb announced the publication of a pivotal U.S. clinical trial for its enVista Envy full range of vision intraocular lens (IOL) in the American Journal of Ophthalmology. The trial results demonstrated that the enVista Envy IOL met all primary efficacy and safety endpoints, showing superior visual performance compared to the enVista monofocal IOL. The study highlighted the lens’s ability to provide a continuous range of vision and excellent tolerance to visual disturbances, positioning it as a promising option for cataract patients seeking comprehensive visual correction.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall stock score reflects a mixed financial performance with ongoing profitability challenges. Positive technical indicators and proactive corporate events provide some optimism, but valuation concerns and neutral earnings sentiment weigh on the score.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company focused on helping people improve their vision and quality of life. The company specializes in eye health products, including intraocular lenses, which are used in cataract surgery to enhance visual performance.
Average Trading Volume: 769,109
Technical Sentiment Signal: Buy
Current Market Cap: $5.31B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.